Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
or

Biodelivery Sci Intl (BDSI)

Biodelivery Sci Intl (BDSI)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
5.59 -0.01 (-0.18%) 03/22/22 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 5.59 unch (unch) -
Quote Overview for Tue, Mar 22nd, 2022
Day Low
5.59
Day High
5.60
Open 5.60
Previous Close 5.60 5.60
Volume 2,107,400 2,107,400
Avg Vol 2,967,275 2,967,275
Stochastic %K 72.89% 72.89%
Weighted Alpha +24.60 +24.60
5-Day Change +0.02 (+0.36%) +0.02 (+0.36%)
52-Week Range 2.50 - 5.62 2.50 - 5.62
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 577,050
  • Shares Outstanding, K 103,229
  • Annual Sales, $ 166,700 K
  • Annual Income, $ 84,860 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 0.56
  • Price/Sales 3.46
  • Price/Cash Flow 15.44
  • Price/Book 2.94
  • Price/Earnings ttm 21.52
  • Earnings Per Share ttm 0.26
  • Most Recent Earnings N/A on 03/10/21
  • Next Earnings Date 05/05/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/22
See More
  • Average Estimate 0.08
  • Number of Estimates 1
  • High Estimate 0.08
  • Low Estimate 0.08
  • Prior Year 0.05
  • Growth Rate Est. (year over year) +60.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.53 +1.08%
on 03/01/22
Period Open: 5.55
5.62 -0.53%
on 02/28/22
+0.04 (+0.72%)
since 02/22/22
3-Month
2.95 +89.49%
on 01/19/22
Period Open: 3.23
5.62 -0.53%
on 02/28/22
+2.36 (+73.07%)
since 12/22/21
52-Week
2.50 +123.60%
on 12/13/21
Period Open: 3.92
5.62 -0.53%
on 02/28/22
+1.67 (+42.60%)
since 03/22/21

Most Recent Stories

More News
Collegium Completes the Acquisition of BDSI

STOUGHTON, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (“Collegium”) today announced that it has completed...

COLL : 29.46 (+1.24%)
BDSI : 5.59 (-0.09%)
BioDelivery Sciences International Announces ELYXYB™ is Now Available in the U.S. for the Acute Treatment of Migraine

The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults Expands BDSI Portfolio...

BDSI : 5.59 (-0.09%)
Pre-Market Brief: Stocks Jump as Geopolitical Tensions in Ukraine Ease

Morning Markets March S&P 500 futures this morning are up +1.29%. U.S. stock index futures are moderately higher this morning on reduced Russia-Ukraine tensions after Russia announced the start of a pullback...

TSLA : 249.98 (+3.86%)
AAPL : 213.49 (+1.82%)
MSFT : 388.56 (+2.58%)
INTC : 24.05 (+1.48%)
NVDA : 121.67 (+5.27%)
AMD : 100.97 (+2.92%)
QCOM : 156.58 (+3.05%)
TXN : 176.42 (+1.62%)
ANET : 83.51 (+4.21%)
MAR : 243.11 (+2.45%)
AMKR : 19.61 (+3.26%)
XOM : 111.90 (+2.97%)
Merger Mania Is Sending These 2 Little-Known Stocks Soaring

Markets opened lower on Monday morning, but nothing held these two companies back.

COMP : 8.76 (+0.34%)
$DOWI : 41,488.19 (+1.65%)
$SPX : 5,638.94 (+2.13%)
$NASX : 17,754.09 (+2.61%)
CNR : 74.26 (+2.40%)
BDSI : 5.59 (-0.09%)
COLL : 29.46 (+1.24%)
BDSI Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of BioDelivery Sciences International, Inc. Is Fair to Shareholders

Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of BioDelivery Sciences International, Inc. (NASDAQ: BDSI) to Collegium Pharmaceutical, Inc. for $5.60 per share is fair...

BDSI : 5.59 (-0.09%)
Pre-Market Brief: Stocks Recover After Ukraine Tensions Ease Slightly

Morning Markets March S&P 500 futures this morning are down -0.07%. U.S. stock index futures initially fell sharply in overnight trade, with March E-mini S&P futures dropping to a 2-week low on inflation...

AAL : 10.87 (+1.87%)
DAL : 46.75 (+6.44%)
UAL : 73.67 (+5.39%)
TXN : 176.42 (+1.62%)
GT : 9.15 (+0.99%)
SPLK : 156.90 (+0.25%)
LMT : 466.17 (-0.38%)
GDDY : 176.15 (+2.16%)
MU : 100.79 (+6.23%)
BDSI : 5.59 (-0.09%)
Collegium to Acquire BioDelivery Sciences in an All-Cash Deal

Transaction is valued at $5.60 per share representing a total equity value of $604 million Represents a 54% premium to BDSI stock’s closing price of $3.64...

BDSI : 5.59 (-0.09%)
Why Shares of BioDelivery Sciences International Jumped 12.2% on Monday

Shares of the small pharmaceutical company, which focuses on pain management, have been rising since it released updated guidance late last week.

COMP : 8.76 (+0.34%)
BDSI : 5.59 (-0.09%)
BioDelivery Sciences Prevails in BELBUCA® ANDA Litigation Maintaining Patent Exclusivity Against Alvogen Until 2032

RALEIGH, N.C., Dec. 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company...

BDSI : 5.59 (-0.09%)
BioDelivery Sciences Reports Solid Third Quarter 2021 Results

Total Net Revenue of $41.1 Million, an Increase of 4% versus Prior Year Strong profitability with GAAP EPS of $0.07, EBITDA Margin of 27% and $7.0 million...

BDSI : 5.59 (-0.09%)
BioDelivery Sciences International to Host ELYXYB™ Investor Day

The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults

BDSI : 5.59 (-0.09%)
BioDelivery Sciences International Completes Acquisition of ELYXYB™ for Acute Migraine Treatment in the U.S. and Canada

Expands Portfolio and Establishes Growth Platform in Neurology

BDSI : 5.59 (-0.09%)
BioDelivery Sciences to Exhibit Three Scientific Posters Comparing BELBUCA® to Oxycodone at the PAINWeek 2021 Conference

RALEIGH, N.C., Sept. 07, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic conditions,...

BDSI : 5.59 (-0.09%)
BioDelivery Sciences to Participate in Upcoming Virtual Investor Conferences

RALEIGH, N.C., Sept. 03, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious...

BDSI : 5.59 (-0.09%)
AzurRx BioPharma Announces Appointment of Terry Coelho to its Board of Directors

AzurRx expands Board of Directors to seven members with new appointment

BDSI : 5.59 (-0.09%)
BCPC : 167.72 (+0.73%)
AZRX : 3.45 (+2.07%)
BioDelivery Sciences Reports Second Quarter 2021 Results

Total Company Net Revenue of $41.4 Million Driven by BELBUCA ® All-Time High TRx Market Share

BDSI : 5.59 (-0.09%)
BioDelivery Sciences Announces Agreement to Acquire U.S. and Canadian Rights to FDA-approved ELYXYB™ for the Acute Treatment of Migraine

The only FDA-approved, ready-to-use oral solution for the acute treatment of migraine with or without aura in adults

BDSI : 5.59 (-0.09%)
BioDelivery Sciences to Report Second Quarter 2021 Financial Results on August 4, 2021

RALEIGH, N.C., July 22, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious...

BDSI : 5.59 (-0.09%)
BioDelivery Sciences Reports First Quarter 2021 Results

Total Company Net Revenue of $41 Million, an Increase of 7% versus Prior Year Net Income of $5.2 Million, EBITDA Margin of 22% and Operating Cash Generation of $11 Million Conference Call and Webcast...

BDSI : 5.59 (-0.09%)
BioDelivery Sciences to Report First Quarter 2021 Financial Results on May 6, 2021

RALEIGH, N.C., April 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious...

BDSI : 5.59 (-0.09%)

Business Summary

BioDelivery Sciences International is a development-stage biotechnology company that is developing and seeking to commercialize a drug delivery technology designed for a potentially broad base of pharmaceuticals, vaccines and over-the-counter drugs. In general, a drug delivery technology refers to any...

See More

Key Turning Points

3rd Resistance Point 5.61
2nd Resistance Point 5.60
1st Resistance Point 5.60
Last Price 5.59
1st Support Level 5.59
2nd Support Level 5.58
3rd Support Level 5.58

See More

52-Week High 5.62
Last Price 5.59
Fibonacci 61.8% 4.43
Fibonacci 50% 4.06
Fibonacci 38.2% 3.69
52-Week Low 2.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.